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Background: Blood pressure irregularities are the precursor to all vascular diseases. Elevated 
systolic blood pressure (BP) is the leading cause of death and disability worldwide. Similarly, 
the burden of dementia is on the rise. BP variability (BPV) has been suggested to be able to 
predict dementia and cognitive impairment more accurately than mean BP. A body of 
literature has shown the link between increased BPV, a high average BP, cognitive 
impairment, and incident dementia. However, the extent of this association is controversial, 
and remains unknown.  
Aim: To identify the magnitude of the association between BPV, cognitive impairment, and 
incident dementia.  
Meta-Analysis: Eleven studies, comprised of 52, 784 individuals, were identified after a 
comprehensive search of the Embase, PsychINFO, PubMed, and Scopus databases. Data was 
extracted and prepared to calculate risk ratios with 95% confidence intervals. Forest plots 
were created. Heterogeneity was identified and publication bias was assessed.  
Results: Systolic BPV was significantly associated with cognitive impairment [RR: 1.29; 
95% CI 1.06 – 1.57; p = 0.01] and overall cognitive decline [RR: 1.23; 95% CI 1.08 – 1.40; p 
= 0.001].  
Conclusion: This meta-analysis has clinical implications on potential clinical interventions 
and treatments for dementia and cognitive impairment. It may also aid in healthcare policy 
regarding patient BP monitoring and modulation. We live in a world with an increasingly 
ageing population, which makes the present a critical time to uncover the relationship 
between BPV and dementia and cognitive impairment.  
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1.1 Dementia and cognitive impairment: aetiology, epidemiology, incidence, prevalence 
Dementia is a chronic syndrome which deteriorates cognitive function beyond the 
extent of normal ageing (Dementia Australia, 2018). It can result from a variety of diseases or 
injuries that affect the brain, such as stroke. The onset is gradual, which often leads to the 
early stage of dementia being overlooked. In the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), dementia is classified as a neurocognitive disorder as it relates to brain 
disease and disrupts cognitive function (American Psychiatric Association, 2013). The 
diagnosis of dementia usually occurs when cognitive impairment becomes severe enough to 
compromise daily life (Hugo & Ganguli, 2014). Mild cognitive impairment (MCI) is a state 
wherein the individual is functional, but is more cognitively impaired than can be explained 
by age. Table 1 shows the DSM-5 diagnosis criteria for dementia. The cognitive domains that 
the diagnosis refers to are complex attention, executive ability, learning and memory, 
language, motor-visual perception, and social cognition (Hugo & Ganguli, 2014).  
Dementia is a major public health issue being the second leading cause of death in 
Australia, and the leading cause of death in females, contributing to 5.4% of all deaths in 
males and 10.6% in females each year (Australian Bureau of Statistics, 2017). In Australia in 
2016, more than 1 in 7 people were over 65 years old. Without a medical breakthrough, the 
incidence of dementia will be greater than half a million by 2028 and more than one million 
by 2058 (Dementia Australia, 2018). There are approximately 250 new cases every day, and 
in 2018, dementia has had a burden of $15 billion dollars on the Australian government 
(Dementia Australia, 2018). On a global level, there are 50 million cases now, and it has been 
projected that by 2050, more than 130 million people worldwide will be diagnosed with 
dementia (Dementia Australia, 2018). 











Mild Neurocognitive Disorder/Dementia 
A Significant cognitive decline in 
one or more cognitive domains, 
based on: 
Modest cognitive decline in one or more 
cognitive domains, based on: 
1. Concern about significant 
decline, expressed by 
individual or reliable 
informant, or observed by 
clinician. 
1. Concern about mild decline, expressed 
by individual or reliable informant, or 
observed by clinician. 
2. Substantial impairment, 
documented by objective 
cognitive assessment. 
2. Modest impairment, documented by 
objective cognitive assessment. 
B Interference with independence in 
everyday activities. 
No interference with independence in 
everyday activities, although these 
activities may require more time and 
effort, accommodation, or compensatory 
strategies 
C Not exclusively during delirium. 
D Not better explained by another mental disorder. 
E Specify one or more etiologic subtypes, “due to” 
 Alzheimer’s disease 
 Cerebrovascular disease (Vascular Neurocognitive Disorder) 
 Frontotemporal Lobar Degeneration (Frontotemporal Neurocognitive 
Disorder) 
 Dementia with Lewy Bodies (Neurocognitive Disorder with Lewy 
Bodies) 
 Parkinson’s disease 
 Huntington’s disease 
 Traumatic Brain Injury 
 HIV Infection 
 Prion Disease 
 Another medical condition 
 Multiple etiologies 
Adapted from:  Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. (as 
cited in Hugo, J., & Ganguli, M. (2014). Dementia and Cognitive Impairment: Epidemiology, 
Diagnosis, and Treatment. Clinics in geriatric medicine, 30(3), 421-442. 
doi:10.1016/j.cger.2014.04.001) 
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Currently treatments are ineffective at reducing the development and progression of 
the disorder (Lattanzi, Luzzi, Provinciali, & Silvestrini, 2014; Williams, 2009). Therefore it is 
critical to identify the risk factors of dementia and MCI to reduce and prevent dementia in the 
long-term, as this would have significant practical implications, such as a clinical approach 
that focuses on mitigating the onset of the disorder.  
One major risk factor for dementia is elevated blood pressure (BP) and hypertension 
(Bermejo-Pareja et al., 2010; Kececi Savan et al., 2016), while another is cerebral small 
vessel disease (CSVD), a type of cerebrovascular disease (Hollocks, Brookes, Morris, & 
Markus, 2016) that is the cause of nearly half of all cases of vascular dementia (Prabhakar et 
al., 2015). The main risk factor of CSVD is also hypertension (Kececi Savan et al., 2016). 
1.2 Hypertension as a risk factor 
Elevated systolic blood pressure (SBP) is a leading cause of death and disability 
worldwide (Lancet, 2017). Hypertension, in itself, is a major public health problem, 
especially for older adults, and is a risk factor for cardiovascular diseases, such as heart 
failure, stroke, and dementia (Gifford et al., 2013). The Heart Foundation (2016) describes 
hypertension as a condition in which an individual’s BP is consistently ≥140/90 mmHg. 
Increased and variable levels of BP play major roles in furthering organ damage and 
triggering subsequent vascular events (Rothwell, 2010). It should be noted that the cognitive 
systems associated with BP flow are allegedly connected to neuroanatomical zones affected 
by dementia and CSVD (Gifford et al., 2013), so cognitive decline may be triggered by BP 
irregularities in these areas.  
However, although hypertension is a risk factor for dementia (Bermejo-Pareja et al., 
2010; Kececi Savan et al., 2016), anti-hypertensive treatments have not shown a significant 
reduction in the incidence and risk of dementia (McGuinness, Todd, Passmore, & Bullock, 
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2006; Peters et al., 2008; Qiu, Winblad, & Fratiglioni, 2005) and cognitive decline (Plassman 
et al., 2010).  
1.3 Types of BP measurements 
There are four ways in which BP can be measured. The first of these is the usual BP, 
which refers to the hypothetical exact underlying level of BP, which can never be measured 
with complete accuracy, but remains to be the most central component of BP. This is because 
it is used to determine the adverse effects depending on the level of BP. The second is the 
mean BP, which is measured as the average of multiple readings of SBP or diastolic blood 
pressure (DBP). Third is blood pressure variability (BPV), which refers to how BP varies 
over time (Rothwell et al., 2010). Lastly, BP instability refers to the fleeting variations in BP, 
usually as a reaction to a stimulus, such as postural change, pain, or emotional strain. 
Instability plays a part in overall BPV, but it differs from BPV in that it refers to abrupt 
changes in BP, which may have different consequences than the more gradual shifts of BPV 
(Rothwell, 2010).  
1.3.1 Blood pressure monitoring 
BP can be measured in many ways. The review, which is the focus for the current 
study, will include all types, including clinic visit-to-visit BP, ambulatory BP monitoring 
(ABPM), and home BP monitoring, so long as there is sufficient data to calculate BPV. 
ABPM is now the gold standard for hypertension diagnosis (Linden, 2011). This is because it 
allows improved accuracy in mean BP calculation (Linden, 2011), and excludes interference 
from the white coat effect (Parati et al., 2008). The mean BP calculated from the ABPM has 
also been found to predict vascular disease and cognitive decline better than clinic visit BP 
(Burr, Dolan, O'Brien, O'Brien, & McCormack, 2008; Salles, Cardoso, & Muxfeldt, 2008), 
although visit-to-visit BP is still a significant risk factor for vascular events, leading on to 
cognitive decline (Qin et al., 2016). Still, patients are not always willing to accept the 
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apparatus that comes with automated ABPM, as cuff inflation may disrupt their daily routines 
and sleep. In these cases, home BP monitoring is a suitable alternative as measurements can 
be taken under consistent conditions over several days (Oishi et al., 2017; Parati et al., 2008).  
1.3.2 Limitations of the usual BP hypothesis  
Hypertension is the most prevalent vascular risk factor and is linked with cognitive 
decline, impairment, and dementia (Gąsecki, Kwarciany, Nyka, & Narkiewicz, 2013; Luzzi, 
Vella, Bartolini, Provinciali, & Silvestrini, 2010; Novak & Hajjar, 2010; Sharp, Aarsland, 
Day, Sønnesyn, & Ballard, 2011). However, this is subject to the limitations of the usual BP 
hypothesis which suggests that the underlying usual BP can account for all related risks, and 
has a beneficial correlation with antihypertensive treatments (Rothwell, 2010).  
The limits of the hypothesis can be described as thus. First, the precision of usual BP 
to be able to predict vascular events declines with age, while the incidence of these events, 
particularly stroke, increases with age (Colandrea, Friedman, Nichaman, & Lynd, 1970; 
Hypertension Detection and Follow-up Program Cooperative Group, 1978; Rothwell et al., 
2004).  Second, it should be noted that the majority of studies on usual BP and vascular risk 
were conducted on healthy samples, excluding those with a medical history of vascular 
events (Prospective Studies Collaboration, 2002). This is despite the fact that individuals 
undergoing antihypertensive treatment are those that have vascular risk factors, or have 
presented them in the past. The samples of these at-risk individuals have shown a discrepancy 
between the predictive mean SBP and BP reduction effects (Rothwell et al., 2010).  
Third, with consideration to the strong predictive association of the morning surge in 
BP and incidence of stroke, the predictive value of mean BP is irrelevant (Kario, Shimada, & 
Pickering, 2003; Wizner et al., 2008). Fourth, the mean BP does not account for temporary 
surges in BP which can trigger vascular events. These surges can be caused by orthostatic 
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hypertension, sympathetic over-activity, and increased blood pressure reactivity due to 
personality traits like anger (Brondolo et al., 2009; Koton et al., 2004).  Fifth, orthostatic 
hypotension, the complete opposite of BP instability, is also a significant risk factor for 
vascular events (Fedorowski et al., 2010), and is also affected by antihypertensive treatments 
(Kamaruzzaman, Watt, Carson, & Ebrahim, 2010).  
Sixth, in the majority of studies, there is no known baseline of SBP that would result 
in a decrease of vascular risk (Prospective Studies Collaboration, 2002). Currently the 
optimal BP range is still unknown (Iadecola et al., 2016); however research has shown that 
individuals with high BPV are at increased risk, despite their mean SBP being considered 
normal (Rothwell et al., 2010). Seventh, situational BPV caused by the white coat effect has 
been linked with increased vascular risk and target-organ damage independent of mean BP 
(Mancia et al., 2009; Mancia, Facchetti, Bombelli, Grassi, & Sega, 2006). This form of 
masked hypertension is also a display of BPV. Eighth, antihypertensive treatments have not 
shown a reduction in dementia risk, as mentioned above (Peters et al., 2008; Skoog et al., 
1996), which suggests that lowering the mean BP is not sufficient to combat and prevent the 
progression of cognitive decline.  
Ninth, specific between group differences, such as gender and ethnicity, cannot be 
accounted for by mean BP with regards to their increased risk of stroke. However, BPV may 
explain the higher incidence of stroke in females (Rothwell et al., 2010) and black people 
(Heuschmann, Grieve, Toschke, Rudd, & Wolfe, 2008). Lastly, the surge in BP post-stroke is 
suggestive of BP instability, and could be a result of similar surges in the past (Rothwell, 
2010).  
All of these lead to the conclusion that usual BP and mean BP are insufficient as the 
sole predictive factors for vascular events, cognitive impairment and the incidence of 
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dementia. However, recent research has shown that measuring BPV seems to be a much more 
significant predictor for all of these cases (Alpérovitch et al., 2014; Rothwell, 2010; Sabayan 
et al., 2013).  
1.3.3 Blood pressure variability 
In recent studies, BPV, as a measure, has been found to be a potential predictor of 
cognitive decline (Conway et al., 2015; Rothwell, 2010), but the extent of this significance is 
unknown. The extent of variability is usually positively associated with mean BP, but can 
also be independent. It is measured as either the overall variability during a set time limit 
(calculated with standard deviation (SD), a coefficient of variation (CV)), or as the mean 
absolute difference between adjacent readings (Rothwell, 2010). Variability can be studied 
over periods of hours on ambulatory monitoring, over minutes during a clinic visit, and over 
days, weeks, months, and years with home BP monitoring or repeated clinic visits (Rothwell 
et al., 2010). 
BPV can be divided into short-term BPV (e.g. a 24 hour cycle with home monitoring 
or ABPM) and long-term BPV (e.g. clinic visit-to-visit BPV over weeks, months, or years), 
both of which are associated with negative outcomes when fluctuations are high. Mechanisms 
of short-term BPV have been attributed to humoral (e.g. viscosity of blood), neural (increased 
sympathetic drive and reduced cardiopulmonary reflexes), and environmental factors (e.g. 
psychological stress, sleep, changes in posture, and physical activity)(Parati, Ochoa, 
Lombardi, & Bilo, 2013). Conversely, knowledge on the mechanisms of long-term BPV is 
still limited to concepts such as increased arterial stiffness, poor BP control of long time 
patients of elevated BP, and seasonal changes (Parati et al., 2013). Negative outcomes of 
these fluctuations involve depression (Scuteri et al., 2009), anxiety, and hostility (Virtanen et 
al., 2003) in the short-term, and cognitive impairment in the long-term (Yano et al., 2014). 
Both are also independently associated with cognitive decline, dementia (Alpérovitch et al., 
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2014; Oishi et al., 2017; Yano et al., 2014), and vascular events (Parati et al., 2013; Rothwell, 
2010).  
1.4 Dementia, cognitive decline, and vascular disease 
Longitudinal studies have demonstrated that BPV increases with age, and has a 
positive correlation with the volume of white matter hyperintensity, which is an indicator for 
CSVD (Brickman, Reitz, Luchsinger, & et al., 2010). CSVD and many other cardiovascular 
events are risk factors for cognitive decline, especially when measured with the CV (Au, 
Massaro, Wolf, & et al., 2006; Nagai, Hoshide, Ishikawa, Shimada, & Kario, 2012).  
Emerging literature considers BPV to have potential value, both in predicting impending 
cognitive decline and vascular events, as well as a possible target for clinical intervention and 
modulation in the treatment of irregular BP.  
1.5 Current study 
1.5.1 Problem statement 
Current literature has demonstrated that there is a link between increased BPV, cognitive 
impairment, and incident dementia (Alpérovitch et al., 2014). BP is the precursor to all 
vascular diseases. It is the main risk factor that can be modified to reduce organ damage, 
especially in the brain following a stroke. Despite this knowledge, standard antihypertensive 
treatments have not yet lead to a decline in the risk of dementia and other cognitive 
impairment (Lattanzi et al., 2014; Williams, 2009). There is also no known optimal BP range 
for brain health. Hence, our current understanding of how to mitigate dementia onset and 
progression is sorely lacking.  
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Although BPV and cognitive impairment have been researched expansively, there is no 
consensus, to date, on the clinical relevance of this association (Dolan & O’Brien, 2015). 
This review will attempt to clarify this via a meta-analysis, which will involve a systematic 
review of all existing literature based on specific inclusion and exclusion criteria. The 
outcomes of all included studies will be compiled, integrated, and then summarized into a 
standard effect size. This will allow for an increase in collective precision and power, when 
compared to any single primary study (Gopalakrishnan & Ganeshkumar, 2013). This review 
may have clinical implications for the diagnosis, prevention, and treatment of vascular 
diseases (e.g. hypertension) and injuries (e.g. stroke), as well as dementia and cognitive 
impairment. We live in an increasingly ageing population, and this is true on a global level. 
This means that the burden of disease, both dementia and vascular, is only going to increase. 
Thus, it is critical to investigate BPV, and its relationship with dementia and cognitive 
impairment.  
1.5.2 Aims 
Recent studies have explored the link between BPV and dementia and cognitive 
impairment. However, the exact extent and magnitude of this association, regarding the SBP 
and DBP and their individual and collective influences on the incidence and rate of dementia 
and cognitive impairment remains is controversial. This review will strive to compile existing 
literature into a cohesive argument, following the standards set by a meta-analysis. 
The primary aims of this review are (1) to assimilate and investigate all available 
literature concerning the relationship between BPV and dementia and cognitive impairment, 
(2) to investigate and identify the magnitude of the relationships of dementia and cognitive 
impairment with BPV, in the forms of SBP and DBP associations of both binary (dementia 
and cognitive impairment) outcomes, and (3) to identify the heterogeneity of the studies.  




2.1 Literature search 
The review protocol was registered on PROSPERO (CRD42017081977). Four 
electronic databases (Embase, PsychINFO, PubMed, and Scopus) were searched from 
inception to June 2018 to source relevant studies examining BPV, dementia, and cognitive 
impairment in an adult population. A research librarian was consulted prior to conducting this 
search to refine search terms and to ensure accuracy. Key terms related to BPV (e.g. ‘blood 
pressure variability’, ‘ambulatory blood pressure monitoring’), dementia and cognitive 
impairment (‘dementia’, ‘cognitive impairment’, ‘cognitive decline’), and 
neuropsychological assessments to identify mental deterioration (‘neuropsychological test’, 
‘neuropsychological assessment’, ‘MMSE’). A search term logic grid was devised for each 
database tailored to their specific indexing term systems (for full logic grids, see Appendix 
A). 
To ensure thorough reporting, no restrictions were set on the date of publication and 
the search terms were kept fairly broad, including both ‘blood pressure variability’ and 
‘hypertension’ more generally to account for alternate labels for BPV and cognitive 
impairment measures. Automatic email alerts for each database were set up to ensure new 
studies published between June and August 2018 meeting the key terms were also covered.  
2.2 Study eligibility 
Studies were included if they recruited individuals that (a) were adults (defined as ≥ 
18 years), (b) had a measure of incident dementia, cognitive impairment, or cognitive decline 
(c) if they had a BPV metric, or sufficient data to calculate a BPV metric, (d) and were 
published in a peer-reviewed journal, to ensure methodological thoroughness and consistency. 
Studies were excluded if they were (a) case studies, (b) reviews, (c) editorials, (d) 
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commentaries, (e) animal studies, or (f) on an underage population, as all of these would lack 
useable data. They were also excluded if they were (g) not published in English, (h) cancer 
studies, (i) gene or genetic studies, (j) surgical intervention studies (e.g. renal denervation), (k) 
had a history of sub-acute stroke in the past four weeks, (l) or had been diagnosed with 
Alzheimer’s at baseline.   
The literature search yielded 6800 publications (Embase = 3961; PsychINFO = 322; 
PubMed = 980; Scopus = 1537), of which 1723 duplicates were removed, leaving 5077 
publications for screening (see figure flowchart). One additional study was added, which met 
criteria, but was not available through the search. Titles and abstracts were evaluated on 
previously defined inclusion and exclusion criteria, and a further 5039 publications were 
removed. A set of 38 full-text articles were reviewed for eligibility based on the availability 
of sufficient data to calculate BPV. A total of 13 studies were identified for inclusion through 
this process. To ensure that there was no confounding due to the overlapping of samples, 
eligible studies were checked to make certain that only studies, with the same samples, which 
reported different outcomes, were included. Two authors were contacted to provide 
additional results for inclusion. These inclusion and exclusion criteria assessments were 
conducted by the research author, in discussion with a senior researcher, for a final sample 
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2.3 Data extraction  
In keeping with the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines, a data extraction spreadsheet was created to compile data for 
each study (Liberati, Altman, Tetzlaff, & et al., 2009). The data obtained for each study, as 
much as possible, included: 
a. Study characteristics: Country; Study design; Sample size; Types of 
neuropsychological assessments used.  
b. Sample demographic characteristics: Mean age (SD); Gender ratio; Percentage 
treated with antihypertensive drugs. 
c. BPV specific information: Method of BP measurement; Interval between 
consecutive measurements; Total duration of consecutive measures; BPV 
calculation method 
d. Follow-up information: Length of follow-up; Number, or %, of participants who 
completed the follow-up. 
2.4 Data preparation 
Data were prepared in several steps. First, BP data, both SBP and DBP, associated with 
dementia and cognitive impairment was extracted from the studies, and standardized so that 
there would be internal consistency. These data included SDs of BP, CVs, hazard ratios, risk 
ratios, and odds ratios, and 95% confidence intervals (CI). In the case of mean SBP and DBP, 
the ratios were standardized to 10mmHg for SBP and 5mmHg for DBP.  In the circumstances 
of the absence of these particular formats of results, BPV metrics were calculated from the 
raw data available in the paper.  
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2.5 Risk of bias assessment 
According to the PRISMA guidelines, the risk of bias of individual studies needs to 
be assessed to gauge the strength and validity of the evidence (Liberati et al., 2009). This is 
due to the varying methodology between studies, as well as different reporting styles. The 
Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool was used to 
assess the risk of bias of each individual study. This tool is recommended by Cochrane for 
evaluating the risk of bias in studies that did not use randomisation. It assesses bias in 
confounding, participant selection, interventions, deviation, missing data, measurement of 
outcomes, and reporting bias (Sterne et al., 2016). The judgments range from low, moderate, 
serious, critical risk of bias, and no information (Sterne et al., 2016).  
A Measurement Tool to Assess Systematic Reviews (AMSTAR) was used to self-
assess the risk of bias and quality of this review. It consists of 16 items, which can be 
answered as ‘Yes’, ‘Partial yes’, or ‘No’. There is no quantitative score generated. Instead, 
the AMSTAR gives an overall confidence rating of the review from the following: high, 
moderate, low, and critically low. This rating suggests the overall confidence in the results of 
the review (Shea et al., 2017).  
2.6 Statistical analyses 
All effect size analyses were conducted using Review Manager (RevMan), version 
5.3. A random effects model was used, to reach a relative risk estimate of the magnitude of 
the association between dementia and cognitive impairment, with the two BP subgroups. The 
estimates were weighted based on the inverse variance, to allow for the overall effect 
estimate to account for the higher variability in data that comes with smaller samples. The 95% 
CIs of the effect estimates of each study were also calculated, to accurately indicate the 
certainty and precision of each estimate. This is because narrower CIs represent higher 
accuracy. Forest plots were produced to represent the distribution of effect estimates for all 
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the studies, as well as to reach a pooled estimate. This would also allow a scaled 
representation of each study, based off their sample size and power (Borenstein, Hedges, 
Higgins, & Rothstein, 2009). 
This review used three measures of heterogeneity to test for variation in outcomes 
between studies. The tau squared statistic estimates the variation in true effect sizes, and also 
assigns weighting to the studies (Borenstein et al., 2009). The chi-squared statistic, also 
known as Cochran’s Q or the Q statistic, tests the significance of heterogeneity by comparing 
the variation to error in the studies (Borenstein et al., 2009). Lastly, the I2 statistic is a relative 
measure for the extent heterogeneity, which is useful for determining the value of further 
subgroup analyses. It describes the variation percentage that is due to heterogeneity, and not 
chance (Borenstein et al., 2009). For this review, the I2 >25% was considered an adequate 
value of heterogeneity (Fletcher, 2007). 
Publication bias may be possible due to the issue of non-significant results having 
lower chances of being published, as well as the exclusion of non-English studies. To reflect 
this, a funnel plot was produced to detect bias, which can be indicated by an asymmetrical 
graphic (Sedgwick, 2013).  
  




3.1 Study and sample characteristics 
Ten journal articles and one conference abstract, published between 2007 and 2018, 
were included in this meta-analysis. The primary countries of recruitment were Japan 
(Nstudies=5) (Fujiwara, Hoshide, Kanegae, Eguchi, & Kario, 2018; Matsumoto et al., 2014; 
Nagai et al., 2012; Oishi et al., 2017; Sakakura, Ishikawa, Okuno, Shimada, & Kario, 2007), 
France (Nstudies=2) (Alpérovitch et al., 2014; Tully, Debette, & Tzourio, 2018), and the 
Netherlands (Nstudies=2)(van Middelaar, van Dalen, van Gool, Moll van Charante, & Richard, 
2016; van Middelaar et al., 2018), alongside a single study from the United Kingdom 
(McDonald, Pearce, Kerr, & Newton, 2017). Böhm et al. (2015)’s multinational study 
involved recruitment from 40 countries. Apart from a cross-sectional study  by Sakakura et al. 
(2007), all other studies had a cohort design.  
Cognitive impairment and decline were measured most commonly by the Mini 
Mental State Examination (MMSE), which was used as a screening tool in all the studies. 
Other measures included the Cambridge Cognition Examination (CAMCOG), Isaac’s Set 
Test, Global Deterioration Scale (GDS), Revised Hasegawa Dementia Scale (HSD-R), Trail 
Making Test, Benton Visual Retention test, and Finger-tapping test. Fujiwara et al. (2018)’s 
study focused specifically on the working memory assessment subsection of the MMSE. 
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3.2 Risk of bias 
 The risk of bias of this review was assessed by AMSTAR, and reported to be a 
moderate quality review. The risk of bias of the individual studies was assessed by ROBINS-
I. All of the studies classified as low risk of bias, except for van Middelaar et al. (2016), 
which was an abstract and lacked sufficient data. Figure 2 shows a summary of the risk of 
bias classifications, in which each item is presented as a percentage across all included 
studies.  
 
Figure 2. Risk of bias graph. 
3.3 Results of individual studies 
The included studies can be divided into two subsets based on the outcomes they are 
measuring: (1) dementia, and (2) cognitive impairment. Alpérovitch et al. (2014) stated that 
individuals, who had suffered high BPV for 4 years or more, were at significantly higher risk 
for dementia, whereas the mean BP was not significantly predictive of this association. Oishi 
et al. (2017) also found results supporting the significance of BPV’s incident dementia 
predictive ability. van Middelaar et al. (2018) reported BPV as a noteworthy predictor of 
cognitive decline, but were unable to find significant associations with incident dementia. Of 
No Information High risk of bias Low risk of bias 
 The Association between BPV, Dementia, and Cognitive Impairment 
25 
 
the eight studies that measured cognitive impairment as an outcome, all showed a significant 
relationship between higher BPV and cognitive decline, except for van Middelaar et al. 
(2016). 
3.4 Relationships between BPV, dementia and cognitive impairment 
3.4.1 Dementia 
The relationship between BPV and dementia can be seen in Tables 2 and 3. There is 
no significant association between BPV, both systolic (p = 0.15) and diastolic (p = 0.1), and 
dementia. The same can also be seen in the association between mean BP and incident 
dementia. There is also no significant difference in predictive power of incident dementia 
between BPV and mean BP (systolic: p = 0.11, diastolic: p = 0.18). However, there may be 



















Association between diastolic BPV and DBP and dementia 
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3.4.2 Cognitive impairment 
The relationship between BPV and cognitive impairment can be seen in Table 4 and 5. 
There is a significant association between systolic BPV and cognitive impairment (p = 0.01), 
but not diastolic BPV (p = 0.39). Neither systolic nor diastolic mean BP have significant 
associations with cognitive impairment. Although systolic BPV has significant predictive 
power, there is no statistically significant difference between BPV and mean BP (systolic: p = 
0.39, diastolic: p = 0.91). 
3.4.3 Combined results 
The relationship between BPV and overall cognitive decline (combines outcomes of 
dementia and cognitive impairment) can be seen in Table 6 and 7. There is a significant 
association between systolic BPV and cognitive decline (p = 0.001), but not diastolic BPV (p 
= 0.09). Neither systolic nor diastolic mean BP have significant associations with cognitive 
decline. There is also no statistically significant difference in the predictive abilities of 
diastolic BPV and mean DBP. However, systolic BPV has significantly better predictive 
power over cognitive decline than mean SBP (p = 0.006).  
No data could be extracted or calculated for the following values: (1) Böhm et al. 
(2015)’s SBP and DBP values, (2) McDonald et al. (2017)’s SBP and DBP values, (3) Oishi 
et al. (2017)’s DBP values, (4) Sakakura et al. (2007)’s DBP and DBPV values, and (5) van 
Middelaar et al. (2016)’s SBP, DBP, and DBPV values. Therefore, these were not 
represented in the forest plots.  
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Table 7  
Association between diastolic BPV and DBP and overall cognitive decline 




 Significant heterogeneity, by means of the Q statistic (chi-squared statistic), was 
observed for all aspects of BPV in relation to dementia, cognitive impairment, and overall 
cognitive decline, which suggests that the true effect sizes varied across studies. However, 
results for the mean BP were a little more diverse. Overall, mean SBP had significant 
heterogeneity (p = 0.03), but DBP did not (p = 0.08). With incident dementia as an outcome, 
there was no significant heterogeneity between groups. However, with the outcome of 
cognitive impairment, both SBP and DBP displayed significant heterogeneity (p = 0.007, p = 
0.02 respectively). This is supported by the corresponding I2 statistics, which were high (i.e. 
I2 > 50%) when the Q statistic was significant. The tau squared statistic estimates the 
variation in true effect sizes (Borenstein et al., 2009), was the largest for mean SBP (Tau2 = 
0.03)  and SBPV (Tau2 = 0.04) against cognitive impairment outcome (Table 4).  
3.6 Publication bias 
 Figures 3 shows the funnel plot for SBPV and SBP in overall cognitive decline. This 
plot was created as the SBPV section consists of more than 10 studies, which is the minimum 
recommended by Cochrane. Figure 3 shows slight asymmetry which suggests that publication 
bias is present. However, it should be noted that there is a possibility of this being superficial 
asymmetry due to the small number of studies.  
 
 




Figure 3. Funnel plot of systolic BPV and SBP associated with overall cognitive decline. 















4.1 Key findings 
 Eleven studies, comprising a pooled sample of 52,784 participants, were identified to 
undergo a systematic review and meta-analysis on the association between BPV and 
dementia and cognitive impairment. The objective of the present review was to collate 
existing literature and identify the magnitude of the links of dementia and cognitive 
impairment with BPV, in the forms of SBP and DBP associations of both binary (dementia 
and cognitive impairment) outcomes. The main results of this meta-analysis show that there 
is a significant association between systolic BPV and cognitive impairment, as well as overall 
cognitive decline. However, this association cannot be found with diastolic BPV. These 
findings will be discussed in detail below, along with the clinical implications and future 
research directions. 
4.1.1 Dementia, cognitive impairment, and overall cognitive decline 
The results show that there is no significant association between BPV and incident 
dementia. This is contrary to the literature which suggests that these two variables do have a 
relationship (Alpérovitch et al., 2014; Rothwell, 2010; Sabayan et al., 2013). However, these 
may be imprecise due to a lack of studies, as there were very few studies focusing on the 
influence BPV has on dementia only (Nstudies = 3).  
With the outcome of cognitive impairment (Nstudies = 8), a significant association was 
found between systolic BPV and cognitive impairment, which supports concepts currently in 
existing literature (Rothwell, 2010; Sabayan et al., 2013). A potential explanation for finding 
significance with this outcome and not incident dementia is the large difference in pooled 
sample sizes.  
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When systolic BPV was evaluated against the combined outcomes of dementia and 
cognitive impairment, the relationship was significant. This is consistent with the current 
literature on the predictive power of systolic BPV as a risk factor of cognitive decline and 
impairment (Conway et al., 2015; Rothwell, 2010; Sakakura et al., 2007). However, this 
finding may also mirror a potentially higher rate of neurocognitive disorders due to 
participant samples having other risk factors for cognitive decline. Naismith, Norrie, 
Mowszowski, and Hickie (2012) have discussed how late life depression and cerebrovascular 
diseases are associated, as well as how they are both risk factors for cognitive decline.  
In this review, systolic BPV was found to have a significant association with 
cognitive decline, but diastolic BPV was not. This is also consistent with previous studies, 
which suggests that while diastolic BPV may be associated with cognitive decline, it is not as 
significant a predictor as systolic BPV (Tully et al., 2018) 
4.1.2 BPV and mean BP 
With emerging research on the increasing predictive power of BPV, mean BP may not 
be the sole indicator of vascular events and irregular BP in future clinical settings. This 
review compared the systolic and diastolic aspects of BPV and mean BP to clarify their 
associations with incident dementia and cognitive impairment.  
Regarding the heterogeneity of the studies, all aspects of BPV were significant in 
relation to incident dementia, cognitive impairment, and overall cognitive decline. This 
showed that there was no overlapping of samples. However, with regards to mean BP, DBP 
only displayed significant heterogeneity with cognitive impairment as an outcome, while SBP 
did the same with cognitive impairment and overall cognitive decline. The lack of significant 
values of heterogeneity could be attributed to the small number of studies in this analysis, 
rather than proving homogeneity of the samples.  
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Considering publication bias (Figure 3), the majority of studies are clustered at the tip 
of the funnel plot, which is a nod at the large sample sizes of the studies. This is due to larger 
sample sizes having higher power and precision. Asymmetry of a funnel plot can be 
attributed to chance, reporting bias, methodology, and heterogeneity (Sterne et al., 2011). In 
this case, the heterogeneity is high, with significance reported by the Q statistic and I2 > 75%, 
which may have influenced asymmetry. However, it is also understood that the stringent 
inclusion and exclusion criteria may also have played a part in contributing to publication 
bias (i.e. peer-reviewed, English). 
There was no significant difference in the associations of mean BP and BPV with 
incident dementia or cognitive impairment, despite systolic BPV being a significant risk 
factor of the latter. However, when it came to overall cognitive decline, the difference 
between systolic BPV and mean SBP was statistically significant (p = 0.006). Matsumoto et 
al. (2014) have also demonstrated that while all of their SBP readings were associated with 
cognitive decline, the association only reached significance when the systolic BPV was used. 
This has some interesting implications for clinical settings that will be discussed in the 
section below.  
Interestingly, standalone BP means (systolic and diastolic) have shown no significant 
association with any of the outcomes. This is strange as a wealth of literature on elevated BP 
and hypertension has earmarked mean SBP as a significant risk factor for vascular events, 
cognitive impairment, and cognitive decline (Bermejo-Pareja et al., 2010; Gifford et al., 2013; 
Kececi Savan et al., 2016). From this, it can be tentatively assumed that mean BP will be 
joined by BPV in future clinical diagnosis, screening, and intervention.  
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4.2 Clinical implications 
 The results of this analysis have some key clinical implications. BP is the precursor to 
all vascular diseases, as well as the main modifiable risk factor. If correctly modulated, it can 
reduce organ damage, especially in the brain following a stroke. Despite this knowledge, 
clinical and pharmaceutical treatments have not been able to prevent or mitigate dementia 
onset and cognitive decline progression (Lattanzi et al., 2014; Williams, 2009). An optimal 
BP range for brain health, in which the risk or rate of cognitive decline decreases, is still 
unknown (Iadecola et al., 2016).  
 Some studies have suggested that a high BPV, specifically systolic BPV,  increases 
the risk of stroke and other vascular events, despite an individual’s mean SBP being in the 
normal range (Nagai, Hoshide, Ishikawa, Shimada, & Kario, 2011; Ogliari et al., 2016; 
Rothwell et al., 2010). As mentioned earlier, BPV increases with age and is positively linked 
with CSVD (Brickman et al., 2010) which, in turn, along with other cardiovascular events are 
risk factors for cognitive decline (Au et al., 2006; Nagai et al., 2012).  
The rate of cognitive decline, for people already afflicted with dementia and cognitive 
impairment, is also faster for those who have higher BPV(Lattanzi et al., 2014), which can be 
seen on cognitive tests assessing attention, processing speed, and memory (Sabayan et al., 
2013).  
In general, this is relevant to both clinicians and researchers. The extent of the 
knowledge on this topic is not sufficient to keep up with an increasingly ageing population, 
which will increase the prevalence and incidence of cognitive impairment and dementia. In 
the future, mean BP will not be the sole assessment of irregular BP. BP monitoring systems, 
such as ABPM or home BP monitoring may become more popular as research has already 
shown that they result in a more accurate representation of a patient’s BP level and 
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fluctuations which, in turn, allow for better diagnosis (Matsumoto et al., 2014; Oishi et al., 
2017).  
In particular, it is important to understand the relationship between mean BP and BPV, 
to allow for modulation interventions of the latter. Currently, antihypertensive treatments 
have been known to have no significant influence or control over BPV, both short-term and 
long-term (Lattanzi et al., 2014; Williams, 2009). Answering this question would enable 
further clinical progress not only in the neurocognitive and neurodegenerative disorders, but 
also in the field of cardiovascular health.  
4.3 Limitations 
Several limitations were evident in this review. First, there is the possibility that not 
all relevant studies may have been included. Every effort was taken to ensure maximal 
coverage (i.e. broad search terms, search strategies, multiple databases). Nevertheless, the 
rigorous inclusion (i.e. peer-reviewed journals) and exclusion (i.e. non-English studies) 
criteria mean that fewer studies were included.  Recently, Jackson and Turner (2017) stated 
that a meta-analysis with less than five studies in a random-effects model might not have any 
more power than the original studies. As a result, the sub-analysis of incident dementia 
against BPV (Nstudies = 3) does not have a strong foundation.  
 Second, moderator analyses were not conducted to clarify the sources of 
heterogeneity. This is partly related to the lack of studies identified. The Cochrane 
Collaboration has set a standard for subgroup analysis, which suggests a minimum of ten 
studies required to detect true differences between groups (Fu et al., 2011), and to avoid the 
pitfall of being underpowered. However, recently it has been demonstrated that a minimum 
of twenty studies may be required (Rubio‐Aparicio, Sánchez‐Meca, López‐López, Botella, & 
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Marín‐Martínez, 2017) to achieve a reliable and satisfactory power level to detect between 
group differences.  
 Third, all of the studies used the MMSE as a screening tool. While there are many 
advantages to it, such as its extensive usage and prominent evidence base, the disadvantages 
are starting to outweigh them. Some of these are its lack of standardisation, expense, 
unsuitability for individuals who are illiterate, and most importantly, its limited effectiveness 
in detecting cognitive impairment and dementia (Carnero-Pardo, 2014; Devenney & Hodges, 
2017; Scazufca, Almeida, Vallada, Tasse, & Menezes, 2009).  There is a need for a more 
developed and insightful neurocognitive tool to replace the MMSE in both research and 
practice.  
4.4 Conclusion  
 BP is inextricably linked with cognition and the health of the brain. It is the most 
easily modifiable risk factor to prevent further triggers to organ damage after a stroke. The 
key finding of this study is a significant association between systolic BPV and cognitive 
impairment and decline.   
The discoveries in this review are valuable for health professionals seeking to 
improve diagnosis, prevention, and treatment of vascular diseases (e.g. hypertension) and 
injuries (e.g. stroke), as well as dementia and cognitive impairment. It may also aid in 
healthcare policy regarding patient BP monitoring and modulation. For the general 
population, this review can serve as a motivation to home monitor BP for irregular 
fluctuations, as this is easy to implement even on an individual level. This can also serve as a 
stepping stone for informing future research on clinical treatments and interventions to 
mitigate dementia onset and slow cognitive decline, as well as to bring an important vascular 
risk factor under control.  
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Table 1: Data extraction summary (study characteristics and sample demographics) 
Study reference Country Cohort name Study  
design 
N  Age  
[M(SD) or 
Median (IQR)] 





Alpertovich 2014 France The Three-City (3C) Study Cohort 9294 73.7 (5.2) 62.0% 50.5% 
Bohm 2015 Intl* ONTARGET, TRANSCEND Cohort 31546 88.0(7.0) 27.5% NR* 
Fujiwara 2018 Japan SEARCH Cohort 525 83.2 (3.2) 55.7% NR* 
Matsumoto 2014 Japan Ohasama Study Cohort 485 63.3(4.7) 72.0% 31.0% 
McDonald 2017 UK NR Cohort 302 72(68-77) 42.0% NR 
Nagai 2012 Japan Shobara City/Soryo Town 
Cohort Study 
Cohort 206 79.9(6.4) 75.0% 71.2% 
Oishi 2017 Japan Hisayama Study Cohort 1674 71.0(7.0) 55.9% 43.3% 
Sakakura 2007 Japan NR Cross-sectional 202 84(3.9) 81.2% 73.3% 
Tully 2018 France The Three-City (3C) Study Cohort 2812 72(69-76) 63.6% NR** 
van Middelaar 2016 Netherlands preDIVA Cohort 2212 74(2.4) NR NR 
van Middelaar 2018 Netherlands preDIVA Cohort 3526 74.2(2.5) 55.20% 54.1% 
 
Intl: International Sample; N: sample size; NR: not reported; M(SD): mean (standard deviation); IQR: interquartile range 
NR* Antihypertensive medication percentages are given by specific medication types 
NR** Antihypertensive medication percentages are given by specific sub sample 




MMSE: Mini Mental State Examination; IST: Isaac’s Set Test; GDS: Global Deterioration Scale; HSD: Hasegawa’s Dementia Scale; HDSR: 
Hasegawa’s Dementia Scale Revised; TRAILS: The Trail Making Test; BVRT: Benton Visual Retention Test; FTT: Finger-tapping test; BP: 
blood pressure; ABPM: ambulatory blood pressure monitoring; BPV: blood pressure variability; CV: coefficient of variation; SD: standard 
deviation; f/up: follow-up 
MMSE* refers to the specific working memory assessment subsection.  


















Alpertovich 2014  MMSE, IST Clinic visit-to-visit 2 years 8 years CV 8 70%  
Bohm 2015  MMSE Clinic visit-to-visit initial 6 weeks,  
6 months 
4.4 years CV 5.4 78%  
Fujiwara 2018  MMSE* ABPM,  
Clinic visit-to-visit 
30 minutes 24 hours SD, CV 1 94.7% 
Matsumoto 2014  MMSE Home 24 hours 4 weeks SD 7.8 NR 
McDonald 2017  MMSE, CAMCOG ABPM 30 minutes (day), 
60 minutes (night) 
24 hours CV 5 67.9%  
Nagai 2012  MMSE, GDS Clinic visit-to-visit 1 month 12 months CV 1 97.6%  
Oishi 2017  MMSE; HDS; HDSR Home 24 hours 28 days CV 5.3 61.5%  
Sakakura 2007  MMSE ABPM 30 minutes 24 hours SD n/a n/a 
Tully 2018  TRAILS, IST, 
BVRT, MMSE, FTT 
Clinic visit-to-visit 2 years 4 years CV 10 NR 
van Middelaar 2016  MMSE Clinic visit-to-visit 2 years 4-8 years CV 8  NR 
van Middelaar 2018  MMSE Clinic visit-to-visit 2 years 6-8 years CV 8  65.4%  
